Dr. Satake is a physician scientist whose philosophy is “bedside to bench to bedside” comprehensive care.
Dr. Satake is a board certified pediatric hematologist and oncologist offering care for children with various cancers. She is also interested in developing new treatments targeting cancers with few adverse effects.
Dr. Satake's research focuses on understanding molecular mechanisms in childhood cancers (and cancer stem cells) and identifying novel targets. The goal of her research is to develop more effective treatments with fewer side effects than current therapies for children with cancers. She has established a tissue repository and developed a series of patient-derived leukemia xenograft mouse models, which serve as precious tools to conduct her research. As a physician-scientist, her ultimate goal is to bring new treatments to her patients.
She is also a certified Zumba instructor. She established virtual exercise classes during the Covid pandemic to promote the physical and mental wellness of her UC Davis colleagues and others. Her passion for exercise has led to an academic project to create a computer tool to make the virtual exercise experience closer to in-person settings. Her goal is to offer this exciting exercise opportunity to patients.
M.D., Asahikawa Medical College, Asahikawa, Japan 1990
Pediatrics, Hokkaido University School of Medicine, Sapporo, Japan 1990-1994
Pediatrics, Wright State University, Dayton OH 2001-2003
Hematology/Oncology, Saitama Cancer Center Hospital, Saitama, Japan 1994-1996
Pediatric Hematology/Oncology, UCLA, Los Angeles CA 2003-2006
Clinician Health and Wellbeing Innovation Award, UC Davis, 2022
Distinguished Alumni Award, Asahikawa Medical School, Japan, 2016
Complete List of Published Work in My Bibliography: http://www.ncbi.nlm.nih.gov/pubmed/?term=NORIKO+SATAKE
Lee AQ, Konishi H, Helmke E, Ijiri M, Lerot JMA, Hicks E, Chien JR, Gorin FA, Satake N. Cmpd10357 to treat B-cell acute lymphoblastic leukemia. Exp Hematol. 2023 Jan 6:S0301-472X(22)00840-2. doi:10.1016/j.exphem.2022.12.005. Epub ahead of print. PMID:36621746.
Lee AQ, Konishi H, Duong C, Yoshida S, Davis RR, Van Dyke JE, Ijiri M, McLaughlin B, Kim K, Li Y, Beckett L, Nitin N, McPherson JD, Tepper CG, Satake N. A distinct subpopulation of leukemia initiating cells in acute precursor B lymphoblastic leukemia: quiescent phenotype and unique transcriptomic profile. Front Oncol. 2022 Sep 21;12:972323. doi:10.3389/fonc.2022.972323. PMID:36212452.
Lee AQ, Ijiri M, Rodriguez R, Gandour-Edwards R, Lee J, Tepper CG, Li Y, Beckett L, Lam K, Goodwin N, Satake N. Novel Patient Metastatic Pleural Effusion-Derived Xenograft Model of Renal Medullary Carcinoma Demonstrates Therapeutic Efficacy of Sunitinib. Front Oncol. 2021 Mar 26;11:648097. doi:10.3389/fonc.2021.648097. PMID:33842362.
Yoshida S, Duong C, Oestergaard M, Fazio M, Chen C, Peralta R, Guo S, Seth PP, Li Y, Beckett L, Nitin N, Satake N. MXD3 antisense oligonucleotide with superparamagnetic iron oxide nanoparticles: A new targeted approach for neuroblastoma. Nanomedicine. 2020 Feb;24:102127. doi:10.1016/j.nano.2019.102127. Epub 2019 Nov 26. PMID:31783139.
Duong C, Yoshida S, Chen C, Barisone G, Diaz E, Li Y, Beckett L, Chung J, Antony R, Nolta J, Nitin N, Satake N. Novel targeted therapy for neuroblastoma: silencing the MXD3 gene using siRNA. Pediatr Res. 2017 Sep;82(3):527-535. doi:10.1038/pr.2017.74. Epub 2017 May 31. PMID:28419087.
Yoshida S, Tuscano E, Duong C, Chung J, Li Y, Beckett L, Tuscano JM, Satake N. Efficacy of an anti-CD22 antibody-monomethyl auristatin E conjugate in a preclinical xenograft model of precursor B-cell acute lymphoblastic leukemia. Leuk Lymphoma. 2017 May;58(5):1254-1257. doi:10.1080/10428194.2016.1235273. Epub 2016 Oct 5. PMID:27701909.